Cannabis for Chronic Pain in Older Adults

The Highest Evidence Grade Strong evidence

Chronic pain is the condition for which cannabis evidence is most robust and the primary reason seniors seek it out. The 2017 National Academies of Sciences, Engineering, and Medicine (NASEM) report, The Health Effects of Cannabis and Cannabinoids, issued its highest evidence grade: "There is conclusive or substantial evidence that cannabis or cannabinoids are effective for the treatment of chronic pain in adults."

This conclusion drew primarily from a systematic review by Whiting and colleagues (2015) of 28 randomized controlled trials involving 2,454 patients, which found cannabinoids were 40% more likely to reduce pain than controls. It remains the foundational meta-analysis in the field.

Subsequent Reviews Have Tempered Enthusiasm

More recent meta-analyses have produced a more nuanced picture — consistent benefits, but modest effect sizes:

• Fisher et al. (2022, PLOS ONE) — Covering 65 RCTs and 7,017 participants, this analysis found that cannabinoids reduced chronic pain, primarily neuropathic pain, but with effect sizes "of questionable importance" that fell below predefined clinically meaningful thresholds.
• 2025 Annals of Internal Medicine — A review of 25 RCTs (2,303 participants, 64% with neuropathic pain) found oral high-THC products reduced pain by approximately 0.78 points on a 0-to-10 scale. Statistically significant, but a modest real-world benefit.

To put that in perspective: a reduction of less than one point on a ten-point pain scale is real — but it is not the dramatic relief that some dispensary marketing implies. Cannabis is best understood as one tool in a comprehensive pain management plan, not a standalone solution.

Neuropathic Pain: The Strongest Subcategory

Within the chronic pain umbrella, neuropathic pain — pain caused by nerve damage from conditions like diabetic neuropathy, post-herpetic neuralgia, or spinal cord injury — consistently shows the strongest response to cannabinoids. A 2024 systematic review found a mean difference of −0.67 on the pain scale across 14 studies.

This subcategory is particularly relevant for seniors, who disproportionately suffer from neuropathic conditions. For older adults whose neuropathic pain has not responded adequately to gabapentinoids or other first-line agents, cannabis may warrant a carefully monitored trial in consultation with their physician.

Fibromyalgia: Very Limited Evidence

Despite strong patient interest, the evidence for cannabis in fibromyalgia is very limited. Only one small crossover trial has been published: a study of nabilone versus amitriptyline in just 32 patients, which found nabilone was more effective for insomnia but not clearly superior for overall fibromyalgia symptoms. No large RCT has been completed for cannabis in fibromyalgia.

Osteoarthritis: A Negative Result

Given that osteoarthritis is the most common form of arthritis among seniors, the evidence gap here is particularly consequential. The first rigorous human RCT — a 12-week study of oral CBD (20–30 mg/day) in 136 patients with hand osteoarthritis, published in Nature (2024) — found no significant difference from placebo on the primary outcome.

This does not definitively prove cannabis cannot help osteoarthritis, but it means the current clinical evidence does not support its use. For more on what is known about topical options, see the Arthritis detail page.

The Opioid-Sparing Question

Whether cannabis can reduce opioid use is one of the most consequential questions in pain medicine, and the evidence is mixed:

• Bradford and Bradford (2016, Health Affairs) — Analyzed Medicare Part D data and found that states with medical cannabis laws had reductions in prescription medication use, with estimated savings exceeding $1 billion if extended nationally. The prescription-reduction evidence is more consistent than mortality data.
• Bachhuber et al. (2014, JAMA Internal Medicine) — Reported a 24.8% lower opioid overdose mortality rate in medical cannabis states. This widely cited finding was subsequently challenged by Shover et al. (2019, PNAS), who extended the analysis through 2017 and found the association reversed direction.

The takeaway: there is suggestive evidence that medical cannabis access may reduce prescription medication use at the population level, but the claim that cannabis prevents opioid deaths has not withstood scrutiny. No senior should unilaterally reduce opioid medications without physician oversight.

Pain Medications and Drug Interactions

Seniors using opioids, NSAIDs, gabapentinoids, or muscle relaxants alongside cannabis face potential drug interactions. CBD inhibits CYP2D6, which metabolizes several opioids including hydrocodone, oxycodone, and tramadol — potentially increasing their blood levels and sedative effects. The combination of any sedating pain medication with THC compounds fall risk.

Before adding cannabis to an existing pain regimen, review your full medication list with a pharmacist. See the Drug Interactions Overview for detailed guidance.